Vontobel Holding Ltd. Raises Stock Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Vontobel Holding Ltd. increased its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 230.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,000 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. Vontobel Holding Ltd.’s holdings in Adaptimmune Therapeutics were worth $41,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Long Focus Capital Management LLC increased its holdings in shares of Adaptimmune Therapeutics by 15.6% in the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after buying an additional 1,662,184 shares during the last quarter. Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares during the last quarter. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics in the first quarter valued at $143,000. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in Adaptimmune Therapeutics during the first quarter valued at about $41,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. StockNews.com upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 13th.

Adaptimmune Therapeutics Trading Down 3.1 %

Shares of ADAP stock opened at $0.78 on Thursday. The business has a 50-day moving average of $1.03 and a 200 day moving average of $1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. Adaptimmune Therapeutics plc has a 1-year low of $0.42 and a 1-year high of $2.05. The stock has a market capitalization of $193.73 million, a PE ratio of -1.09 and a beta of 2.20.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The firm had revenue of $128.23 million during the quarter, compared to analyst estimates of $58.00 million. As a group, sell-side analysts anticipate that Adaptimmune Therapeutics plc will post -0.23 earnings per share for the current year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.